PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer
PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use Read More
Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature
PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788–1793. Published online 2010 Nov 16. doi: 10.1038/sj.bjc.6605916. AUTHORS: M. Knauer, F. Cardoso, J. Wesseling, P.L. Bedard, S.C. Linn, E.J.T. Rutgers, and L.J. van't Veer Background: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk Read More
Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients with Early Stage Breast Cancer
PUBLICATION: Int J Mol Med. 2010 Dec;26(6):837-43. AUTHORS: Gevensleben H., Göhring U.J., Büttner R., Heukamp L.C., Kunz G., Dimpfl T., Jackisch C., Ortmann O., Albert U.S., Bender R., De Snoo F., Krijgsman O., Glas A.M., Ergönenc Y.H., Vogel C., Dykgers A., Langwieder C., Rees M., Anzeneder T. SUMMARY: Thirty-two percent Read More
Biological Functions of the Genes in the MammaPrint® Breast Cancer Profile Reflect the Hallmarks of Cancer
PUBLICATION: Biomarker Insights. 2010 Nov 28;5:129-38. doi: 10.4137/BMI.S6184. AUTHORS: Tian S., Roepman P., Van't Veer L.J., Bernards R., de Snoo F., Glas A.M. SUMMARY: The study included 3090 clinical low-risk patients with unifocal and 238 patients with multifoGenes in the MammaPrint gene signature comprehensively measure the six hallmarks of cancer-related Read More
MammaPrint® Translating Research into a Diagnostic Test
PUBLICATION: Molecular Diagnostics: The Key in Personalized Cancer Medicine 2010; pg. 26; Chapter 7 AUTHORS: Annuska M. Glas, Leonie Delahaye, Oscar Krijgsman SUMMARY: Book Chapter: This chapter describes all important critical steps being met for the implementation of a multi-marker microarray (MammaPrint®) as a routine diagnostic tool. Read more: MammaPrint Read More
Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer
PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30. AUTHORS: Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. SUMMARY: Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen Read More
Metastatic Potential of T1 Breast Cancer Can Be Predicted by the 70-gene MammaPrint Signature
PUBLICATION: Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22. AUTHORS: Mook S., Knauer M., Bueno-de-Mesquita J.M., Retel V.P., Wesseling J., Linn S.C., Van't Veer L.J., Rutgers E.J. SUMMARY: The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 87% (SE 2%) and 91% (SE Read More
